文献速递核素与放射性配体治疗肿瘤 PET/CT

基于PET/CT的90Y选择性内放射治疗吸收剂量图与动态MRI衍生的肝功能空间变化相关

PET/CT-Based Absorbed Dose Maps in 90Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI.
PubMed 文献 · J Nucl Med · 2024-08-01

本研究纳入11例接受90Y选择性内放射治疗(SIRT)的肝恶性肿瘤患者,比较治疗前后动态钆塞酸增强MRI生成的肝实质功能指标k1图与90Y PET/CT吸收剂量(AD)体素图的空间对应关系。多数患者(8/11)中k1丢失与AD呈显著正相关(ρ=0.53-0.99,P<0.001),提示较高AD与局部肝细胞功能较大丢失相关。

要点

  • 多数患者(8/11)中k1丢失与AD呈显著正相关(ρ=0.53-0.99,P<0.001)。
  • 9例患者平均k1丢失与AD强相关(ρ≥0.92,P<0.001),约100 Gy处k1丢失约25%。
  • 肝细胞癌、较高丙氨酸转氨酶、较大NTL接受AD≥70 Gy体积分数及序贯SIRT患者k1丢失更大。

核心结论

  • 多模态影像的新应用显示90Y SIRT的AD与空间肝功能肝实质退化相关,较高AD与局部肝细胞功能较大丢失相关。
  • 作者认为,基于所建立的响应模型,PET衍生的AD图可能有助于前瞻性识别肝脏局部损伤并优化治疗策略。

研究设计与样本

  • 研究纳入11例接受90Y SIRT的患者,治疗前后采集动态钆塞酸增强MRI并生成k1图。
  • 由90Y PET/CT扫描生成体素AD图并按AD分箱,将治疗前后k1图与AD图配准,计算各箱k1绝对丢失和百分比丢失。
  • 对每例患者评估k1丢失与AD的Spearman相关系数,并将患者平均k1丢失按AD拟合三参数逻辑函数。
  • 患者按病灶类型、基线白蛋白-胆红素评分和丙氨酸转氨酶水平、剂量-体积效应及SIRT治疗次数分层分析。

主要发现

  • 多数患者(8/11)中k1绝对丢失和百分比丢失与AD均呈显著正相关(ρ=0.53-0.99,P<0.001)。
  • 9例患者平均k1丢失与AD呈显著强相关(ρ≥0.92,P<0.001)。
  • 患者跨AD箱的平均百分比k1丢失为28%,逻辑函数模型显示约100 Gy处k1丢失约25%。
  • 亚组分析显示,肝细胞癌、较高丙氨酸转氨酶水平、较大非肿瘤肝接受AD≥70 Gy体积分数及序贯SIRT治疗的患者k1丢失更大。

关键数值与推荐

  • 多数患者(8/11)中k1丢失与AD的Spearman相关系数ρ=0.53-0.99,P<0.001。
  • 9例患者平均k1丢失与AD的Spearman相关系数ρ≥0.92,P<0.001。
  • 患者跨AD箱的平均百分比k1丢失为28%,逻辑函数模型显示约100 Gy处k1丢失约25%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Functional liver parenchyma can be damaged from treatment of liver malignancies with 90Y selective internal radiation therapy (SIRT). Evaluating functional parenchymal changes and developing an absorbed dose (AD)-toxicity model can assist the clinical management of patients receiving SIRT. We aimed to determine whether there is a correlation between 90Y PET AD voxel maps and spatial changes in the nontumoral liver (NTL) function derived from dynamic gadoxetic acid-enhanced MRI before and after SIRT. Methods: Dynamic gadoxetic acid-enhanced MRI scans were acquired before and after treatment for 11 patients undergoing 90Y SIRT. Gadoxetic acid uptake rate (k1) maps that directly quantify spatial liver parenchymal function were generated from MRI data. Voxel-based AD maps, derived from the 90Y PET/CT scans, were binned according to AD. Pre- and post-SIRT k1 maps were coregistered to the AD map. Absolute and percentage k1 loss in each bin was calculated as a measure of loss of liver function, and Spearman correlation coefficients between k1 loss and AD were evaluated for each patient. Average k1 loss over the patients was fit to a 3-parameter logistic function based on AD. Patients were further stratified into subgroups based on lesion type, baseline albumin-bilirubin scores and alanine transaminase levels, dose-volume effect, and number of SIRT treatments. Results: Significant positive correlations (ρ = 0.53-0.99, P < 0.001) between both absolute and percentage k1 loss and AD were observed in most patients (8/11). The average k1 loss over 9 patients also exhibited a significant strong correlation with AD (ρ ≥ 0.92, P < 0.001). The average percentage k1 loss of patients across AD bins was 28%, with a logistic function model demonstrating about a 25% k1 loss at about 100 Gy. Analysis between patient subgroups demonstrated that k1 loss was greater among patients with hepatocellular carcinoma, higher alanine transaminase levels, larger fractional volumes of NTL receiving an AD of 70 Gy or more, and sequential SIRT treatments. Conclusion: Novel application of multimodality imaging demonstrated a correlation between 90Y SIRT AD and spatial functional liver parenchymal degradation, indicating that a higher AD is associated with a larger loss of local hepatocyte function. With the developed response models, PET-derived AD maps can potentially be used prospectively to identify localized damage in liver and to enhance treatment strategies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lu Z, Polan DF, Wei L, et al. PET/CT-Based Absorbed Dose Maps in 90Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI. J Nucl Med. 2024. PMID: 38960710. doi:10.2967/jnumed.124.267421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。